IRIS
GIORDANO, GUIDO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 1.241
AS - Asia 1.181
NA - Nord America 989
SA - Sud America 272
AF - Africa 17
OC - Oceania 1
Totale 3.701
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 946
SG - Singapore 532
IE - Irlanda 416
CN - Cina 247
BR - Brasile 224
HK - Hong Kong 202
RU - Federazione Russa 192
SE - Svezia 174
IT - Italia 160
DE - Germania 110
VN - Vietnam 82
GB - Regno Unito 36
UA - Ucraina 36
FI - Finlandia 30
AE - Emirati Arabi Uniti 23
FR - Francia 21
BD - Bangladesh 19
CA - Canada 17
AR - Argentina 16
IN - India 16
MX - Messico 16
PL - Polonia 14
NL - Olanda 11
VE - Venezuela 10
ZA - Sudafrica 10
AT - Austria 9
CZ - Repubblica Ceca 9
TR - Turchia 9
ID - Indonesia 8
JP - Giappone 8
ES - Italia 7
IQ - Iraq 7
PY - Paraguay 6
EC - Ecuador 5
AZ - Azerbaigian 4
CL - Cile 4
LT - Lituania 4
SA - Arabia Saudita 4
UZ - Uzbekistan 4
JO - Giordania 3
RO - Romania 3
BE - Belgio 2
CO - Colombia 2
ET - Etiopia 2
NO - Norvegia 2
OM - Oman 2
TT - Trinidad e Tobago 2
UY - Uruguay 2
AL - Albania 1
AM - Armenia 1
BO - Bolivia 1
BW - Botswana 1
CG - Congo 1
CI - Costa d'Avorio 1
CR - Costa Rica 1
DK - Danimarca 1
DO - Repubblica Dominicana 1
EG - Egitto 1
GR - Grecia 1
GT - Guatemala 1
GY - Guiana 1
HN - Honduras 1
HT - Haiti 1
IL - Israele 1
IR - Iran 1
IS - Islanda 1
JM - Giamaica 1
KG - Kirghizistan 1
KZ - Kazakistan 1
LB - Libano 1
ME - Montenegro 1
MY - Malesia 1
NI - Nicaragua 1
NP - Nepal 1
NZ - Nuova Zelanda 1
PE - Perù 1
PH - Filippine 1
SV - El Salvador 1
TH - Thailandia 1
TJ - Tagikistan 1
TN - Tunisia 1
Totale 3.701
Salva come PNG Salva come JPEG
Città #
Dublin 415
Singapore 243
Hong Kong 202
Ashburn 165
Dallas 153
Nyköping 134
Beijing 109
Santa Clara 90
Munich 54
New York 43
Ho Chi Minh City 36
Princeton 35
Chandler 34
Moscow 34
São Paulo 33
The Dalles 29
Jacksonville 27
Helsinki 20
Hanoi 18
Seattle 18
Los Angeles 17
Wilmington 16
Frankfurt am Main 15
Brooklyn 12
Milan 11
Warsaw 11
Düsseldorf 10
Rome 10
Bari 9
Brno 9
Turku 9
Grosseto 8
London 8
Nuremberg 8
Rio de Janeiro 8
Amsterdam 7
San Francisco 7
Chennai 6
Falkenstein 6
Johannesburg 6
Mexico City 6
Montreal 6
Shanghai 6
Tokyo 6
Washington 6
Andria 5
Belo Horizonte 5
Boston 5
Chicago 5
Des Moines 5
Dhaka 5
Guangzhou 5
Manchester 5
Stockholm 5
Assago 4
Borås 4
Brasília 4
Chengdu 4
Haiphong 4
Martina Franca 4
Noicattaro 4
Phoenix 4
Porto Alegre 4
Potenza 4
Pune 4
Tashkent 4
Amman 3
Ankara 3
Biên Hòa 3
Bologna 3
Changsha 3
Curitiba 3
Foggia 3
Lauterbourg 3
Manaus 3
Marostica 3
Miami 3
Modugno 3
Ottawa 3
Pescara 3
Portsmouth 3
San Jose 3
San Mateo 3
Sorocaba 3
St Petersburg 3
São José do Rio Preto 3
Toronto 3
Viamão 3
Wuxi 3
Addis Ababa 2
Ajman 2
Atlanta 2
Baghdad 2
Baku 2
Barquisimeto 2
Bauru 2
Belém 2
Bitonto 2
Boardman 2
Bình Dương 2
Totale 2.299
Salva come PNG Salva come JPEG
Nome #
Eribulin Treatment in Patients with Liver Metastatic Breast Cancer: Eight Italian Case Reports 93
Obstructive Sleep Apnea Worsens Progression-Free and Overall Survival in Human Metastatic Colorectal Carcinoma 86
Centrosome linker–induced tetraploid segregation errors link rhabdoid phenotypes and lethal colorectal cancers 82
Differential and divergent activity of insulin-like growth factor binding protein 6 in platinum-sensitive versus platinum-resistant high-grade serous ovarian carcinoma cell lines 80
Immune escape mechanisms in colorectal cancer pathogenesis and liver metastasis 79
Crosstalk between the tumor microenvironment and immune system in pancreatic ductal adenocarcinoma: Potential targets for new therapeutic approaches 79
NAB-paclitaxel and gemcitabine in metastatic pancreatic ductal adenocarcinoma (PDAC): From clinical trials to clinical practice 79
Evidence‐based second‐line treatment in ras wild‐type/mutated metastatic colorectal cancer in the precision medicine era 76
Complete response to capecitabine in a frail, elderly patient with metastatic colorectal cancer: A case report 75
Aberrant BLM cytoplasmic expressionassociates with DNA damage stress and hypersensitivity to DNA-damaging agents in colorectal cancer 74
Cancer-Associated Immune Resistance and Evasion of Immune Surveillance in Colorectal Cancer 73
CROC-Mutated rhabdoid colorectal carcinoma showing in intracellular spaces lamellipodia and cellular projectionts revealed by electron microscopy 73
Cancer drug related cardiotoxicity during breast cancer treatment 71
Pancreatic Enzyme Replacement and Nutritional Support With nab-Paclitaxel-based First-Line Chemotherapy Regimens in Metastatic Pancreatic Cancer 69
Cancer-related CD15/FUT4 overexpression decreases benefit to agents targeting EGFR or VEGF acting as a novel RAF-MEK-ERK kinase downstream regulator in metastatic colorectal cancer 69
Colonic Ewing Sarcoma/PNET associated with liver metastases: A systematic review and case report 68
Morphology and molecular features of rare colorectal carcinoma histotypes 65
Eribulin plus trastuzumab in pretreated HER2-positive advanced breast cancer patients: safety and efficacy. An Italian experience. 64
TRAP1 regulates the response of colorectal cancer cells to hypoxia and inhibits ribosome biogenesis under conditions of oxygen deprivation 63
Cetuximab continuation after first progression in metastatic colorectal cancer (CAPRI-GOIM): A randomized phase II trial of FOLFOX plus cetuximab versus FOLFOX 62
Emerging insight into MAPK inhibitors and immunotherapy in colorectal cancer 60
Urothelial bladder carcinoma metastasizing to the eye: A systematic review and case report 60
Circulating Tumor DNA: A New Research Frontier in Urological Oncology from Localized to Metastatic Disease 58
Eribulin for metastatic breast cancer (MBC) treatment: A retrospective, multicenter study based in Campania, south Italy (Eri-001 trial) 58
Targeting Angiogenesis and Tumor Microenvironment in Metastatic Colorectal Cancer: Role of Aflibercept 58
What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 1: Focus on Immunohistochemical Results with Discussion of Pre-Analytical and Interpretation Variables 57
Androgen receptor, PARP signaling, and tumor microenvironment: the ‘perfect triad’ in prostate cancer? 57
JAK/Stat5-mediated subtype-specific lymphocyte antigen 6 complex, locus G6D (LY6G6D) expression drives mismatch repair proficient colorectal cancer 56
Role of Etiology in Hepatocellular Carcinoma Patients Treated with Lenvatinib: A Counterfactual Event-Based Mediation Analysis 55
Germinal BRCA1-2 pathogenic variants (gBRCA1-2pv) and pancreatic cancer: epidemiology of an Italian patient cohort 55
Bcl-10, trypsin and synaptophysin helps recognize acinar cell and mixed acinar neuroendocrine cell carcinoma of the pancreas on both preoperative cytological samples and needle biopsy specimens 53
Activity and Safety of NAB-FOLFIRI and NAB-FOLFOX as First-Line Treatment for metastatic Pancreatic Cancer (NabucCO Study) 53
Altered centriolar cohesion by CEP250 and appendages impact outcome of patients with pancreatic cancer 52
Eribulin in male patients with breast cancer: The first report of clinical outcomes 52
Dose intensity and efficacy of the combination of everolimus and exemestane (EVE/EXE) in a real-world population of hormone receptor-positive (ER+/PgR+), HER2-negative advanced breast cancer (ABC) patients: a multicenter Italian experience 52
Real-World Outcomes and Molecular Profiling for Patients with Metastatic Castration-resistant Prostate Cancer with Lung Metastases: A Long-term Multicenter Experience 52
Different Genomic Clusters Impact on Responses in Advanced Biliary Tract Cancer Treated with Cisplatin Plus Gemcitabine Plus Durvalumab 52
Clinical activity and tolerability of FOLFIRI and cetuximab in elderly patients with metastatic colorectal cancer in the CAPRI-GOIM first-line trial 51
Solitary metastasis from renal cell carcinoma to the choroid plexus: A case illustration and review of the literature 51
Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic variants (gBRCA1-2pv): a multicenter survey 48
Metastatic melanoma: An unusual presentation 47
The classification of neuroendocrine neoplasms of the lung and digestive system according to WHO, 5th edition: similarities, differences, challenges, and unmet needs 44
Initial management approach for localized/locally advanced disease is critical to guide metastatic castration-resistant prostate cancer care 42
What do we have to know about pd-l1 expression in prostate cancer? A systematic literature review. part 1: Focus on immunohistochemical results with discussion of pre-analytical and interpretation variables 42
Solitary fibrous tumor/hemangiopericytoma of the cervical spine: A systematic review of the literature with an illustrative case 41
Centrosome Dynamics and Its Role in Inflammatory Response and Metastatic Process 41
Immune resistance and egfr antagonists in colorectal cancer 41
Primary versus secondary antiemetic prophylaxis with NK1 receptor antagonists in patients affected by gastrointestinal malignancies and treated with a doublet or triplet combination regimen including oxaliplatin and/or irinotecan plus fluoropyrimidines: A propensity score matched analysis 41
What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 3: PD-L1, Intracellular Signaling Pathways and Tumor Microenvironment 40
What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 5: Epigenetic Regulation of PD-L1 40
What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 4: Experimental Treatments in Pre-Clinical Studies (Cell Lines and Mouse Models) 39
Recurrent Glioblastoma Treatment: State of the Art and Future Perspectives in the Precision Medicine Era 37
The role of nanoliposomal irinotecan plus fluorouracil/leucovorin in the continuum of care of patients with metastatic pancreatic ductal adenocarcinoma 37
What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 2: Clinic-Pathologic Correlations 37
What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review (Part 6): Correlation of PD-L1 Expression with the Status of Mismatch Repair System, BRCA, PTEN, and Other Genes 37
MiRNA expression affects survival in patients with obstructive sleep apnea and metastatic colorectal cancer 36
Tumor treating fields for the treatment of glioblastoma: Current understanding and future perspectives 36
TRAP1 modulates mitochondrial biogenesis via PGC-1α/TFAM signalling pathway in colorectal cancer cells 36
Nano albumin bound-paclitaxel in pancreatic cancer: Current evidences and future directions 36
Real-world comparative effectiveness of nab-paclitaxel plus gemcitabine versus FOLFIRINOX in advanced pancreatic cancer: a systematic review 36
What do we have to know about pd-l1 expression in prostate cancer? A systematic literature review. part 5: Epigenetic regulation of pd-l1 35
What do we have to know about PD-L1 expression in prostate cancer? A systematic literature review. part 4: Experimental treatments in pre-clinical studies (cell lines and mouse models) 35
Third whole-brain radiation therapy for multiple brain metastases. Should it be considered in selected patients? 34
What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 3: PD-L1, Intracellular Signaling Pathways and Tumor Microenvironment 34
Clinical outcomes and response to chemotherapy in a cohort of pancreatic cancer patients with germline variants of unknown significance (VUS) in BRCA1 and BRCA2 genes 34
Single-cell proteo-genomic reveals a comprehensive map of centrosome-associated spliceosome components 33
Multidisciplinary management of HER2-positive breast cancer with brain metastases: An evidence-based pragmatic approach moving from pathophysiology to clinical data 32
Wnt (canonical and non canonical) pathways in breast carcinoma with extensive vascular invasion and inflammatory breast carcinoma 32
What do we have to know about pd-l1 expression in prostate cancer? A systematic literature review. part 2: Clinic–pathologic correlations 30
MHC class III lymphocyte antigens 6 as endogenous immunotoxins: Unlocking immunotherapy in proficient mismatch repair colorectal cancer 29
Lymphocyte antigen 6G6D-mediated modulation through p38α MAPK and DNA methylation in colorectal cancer 29
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: A large real-life worldwide population 27
Germline pathogenic variants of cancer predisposition genes in a multicentre Italian cohort of pancreatic cancer patients 26
Loss of Primary Cilia Potentiates BRAF/MAPK Pathway Activation in Rhabdoid Colorectal Carcinoma: A Series of 21 Cases Showing Ciliary Rootlet CoiledCoil (CROCC) Alterations 26
Molecular and Clinical Insights in Malignant Brenner Tumor of the Testis With Liver Metastases:A Case Report 25
Propensity for Early Metastatic Spread in Breast Cancer: Role of Tumor Vascularization Features and Tumor Immune Infiltrate 25
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real‐world data 25
Exploring external validity of chemotherapy for pancreatic ductal adenocarcinoma in real life 25
Durvalumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Biliary Tract Cancer: a Real-World Retrospective, Multicenter Study 24
Prognostic analysis and outcomes of metastatic pancreatic cancer patients receiving nab‐paclitaxel plus gemcitabine as second or later‐line treatment 22
Evaluating CDK4/6 Inhibitor Therapy in Elderly Patients with Metastatic Hormone Receptor-Positive, HER2-Negative Breast Cancer: A Retrospective Real-World Multicenter Study 22
Second-line therapy in pancreatic ductal adenocarcinoma (PDAC) patients with germline BRCA1-2 pathogenic variants (gBRCA1-2pv) 21
A Prognostic Index for Advanced Biliary Tract Cancer Treated With Cisplatin, Gemcitabine and Durvalumab: The MAGIC-D Index 9
Real-life second-line therapies outcome in metastatic pancreatic cancer (mPDAC) patients previously treated with gemcitabine plus nab-paclitaxel (Gem-Nab): An Italian multicenter study 8
CDK4/6 Inhibitors in Patients Aged 80 and Older with HR+/HER2− Metastatic Breast Cancer: A Real-World Multicenter Study 8
Negative impact of corticosteroid use on outcome in patients with advanced BTCs treated with cisplatin, gemcitabine, and durvalumab: A large real-life worldwide population 4
Factors associated with reaching maintenance therapy in patients with advanced biliary tract cancer treated with durvalumab: Real-world results from a multicenter and multinational study 3
Totale 4.013
Salva come PNG Salva come JPEG
Categoria #
all - tutte 33.269
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 33.269
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021161 0 0 0 0 0 0 35 65 27 33 0 1
2021/2022150 3 0 1 1 10 2 11 15 21 39 2 45
2022/2023803 80 23 47 7 35 53 7 46 433 8 48 16
2023/2024275 27 23 25 19 24 77 13 22 5 3 2 35
2024/20251.360 47 23 33 105 43 272 94 116 229 116 136 146
2025/20261.264 161 339 248 292 145 79 0 0 0 0 0 0
Totale 4.013